VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Preterm Infants Developing Normally Clinical Trial

Official title:

VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00564161
• Other study ID #: 606060-HMO-CTIL
• Secondary ID: 606060-HMO-CTIL
• Status: Withdrawn
• Phase: N/A
• First received: November 25, 2007
• Last updated: September 1, 2016
• Start date: January 2008
• Est. completion date: January 2009

Study information

• Verified date: November 2007
• Source: Hadassah Medical Organization
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Observational

Clinical Trial Summary

We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 25 Weeks to 40 Weeks

Eligibility

Inclusion Criteria:

• Preterm infants undergoing lumbar puncture.

Exclusion Criteria:

• Preterm with IVH or known infection or meningitis.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Premature Birth
• Preterm Infants Developing Normally
• Preterm Infants With White Matter Damage

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hadassah Medical Organization